Assetmark Inc. raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 9.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,759 shares of the biotechnology company's stock after buying an additional 3,734 shares during the quarter. Assetmark Inc.'s holdings in Sarepta Therapeutics were worth $5,199,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Manchester Capital Management LLC grew its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. raised its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank lifted its position in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics during the fourth quarter worth $36,000. 86.68% of the stock is owned by institutional investors.
Sarepta Therapeutics Trading Down 1.0 %
Shares of NASDAQ:SRPT traded down $0.98 during trading on Wednesday, hitting $99.73. 402,479 shares of the company's stock were exchanged, compared to its average volume of 913,128. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $9.68 billion, a P/E ratio of 79.79 and a beta of 0.79. The firm has a 50-day moving average price of $113.27 and a two-hundred day moving average price of $120.70. Sarepta Therapeutics, Inc. has a 1-year low of $97.91 and a 1-year high of $173.25.
Insiders Place Their Bets
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.
Analyst Ratings Changes
SRPT has been the subject of a number of recent research reports. Needham & Company LLC restated a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Royal Bank of Canada dropped their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price objective on the stock. StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Scotiabank started coverage on Sarepta Therapeutics in a research report on Friday, March 7th. They set a "sector perform" rating and a $105.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $170.41.
View Our Latest Stock Report on SRPT
About Sarepta Therapeutics
(
Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
